K-Ras Peptide Mimotope Induces Antigen Specific Th1 and B-Cell Immune Responses against G12A-Mutated K-Ras Antigen in Balb/c Mice
<i>KRAS</i> G12A somatic point mutation in adenocarcinomas is categorized clinically as ineligibility criteria for anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies. In this study, a modified G12A-K-ras epitope (139A) with sequence-specific modifications to improve immunogen...
Spremljeno u:
| Glavni autori: | , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
MDPI AG
2021-02-01
|
| Serija: | Vaccines |
| Teme: | |
| Online pristup: | https://www.mdpi.com/2076-393X/9/3/195 |
| Oznake: |
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|
